SM03, an anti-human CD22 monoclonal antibody, for active rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled study

医学 类风湿性关节炎 随机对照试验 内科学 安慰剂 胃肠病学 双盲 不利影响 安慰剂对照研究 病理 替代医学
作者
Jing Li,Mengtao Li,Di Wu,Jiaxin Zhou,Shui‐on Leung,Fengchun Zhang
出处
期刊:Rheumatology [Oxford University Press]
卷期号:61 (5): 1841-1848 被引量:17
标识
DOI:10.1093/rheumatology/keab699
摘要

OBJECTIVE: SM03, a novel chimaeric mAb specific to B cell-restricted antigen CD22, has been developed to treat RA and other B-cell-related diseases. This 24-week phase II randomized, double-blind, multi-dose, placebo-controlled study aimed to evaluate the efficacy and safety of SM03 in moderately-to-severely active RA patients in China. METHODS: One hundred and fifty-six patients on background MTX were randomized in a 1:1:1 ratio to receive a cumulative dose of 3600 mg (high dose, 600 mg × 6 infusions at weeks 0, 2, 4, 12, 14 and 16) or 2400 mg SM03 (low dose, 600 mg × 4 infusions at weeks 0, 2, 12 and 14) or the placebo. The primary outcome was the 24-week ACR 20% improvement criteria (ACR20) response rate. Safety was also assessed. RESULTS: The 24-week ACR20 response rate was significantly higher with high- (65.3%, P = 0.002) and low-dose SM03 (56.9%, P = 0.024) than with placebo (34.0%), but comparable between the high- and low-dose group. The rate of adverse events was not statistically different among the high-dose group (35.3%), the low-dose group (51.9%) and the placebo group (34.6%). Thirteen (12.6%) patients receiving SM03 reported treatment-emergent infections, including 3.9% patients in the high-dose group. No patients reported severe treatment-emergent infections or malignancies. CONCLUSIONS: In active RA Chinese patients receiving background MTX, SM03 at a cumulative dose of both 2400 mg and 3600 mg is efficacious and well-tolerated throughout the 24 weeks of treatment. Moreover, SM03 has demonstrated a good safety profile. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT04192617.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
岁末完成签到 ,获得积分20
刚刚
jeff发布了新的文献求助10
刚刚
吉吉完成签到 ,获得积分10
刚刚
甜甜发布了新的文献求助10
刚刚
完美访烟完成签到,获得积分10
刚刚
1秒前
秋风的应助被张博采纳,获得10
1秒前
1秒前
1秒前
遇见完成签到,获得积分10
1秒前
大意的忆寒完成签到,获得积分10
1秒前
1秒前
04d的应助被gaoyiqing采纳,获得10
2秒前
妍宝贝完成签到 ,获得积分10
2秒前
端庄南莲完成签到,获得积分10
2秒前
现代的雯完成签到,获得积分10
2秒前
2秒前
吹梦西洲发布了新的文献求助10
2秒前
3秒前
DR_XU发布了新的文献求助10
3秒前
爆米花的应助被蒲公英采纳,获得10
3秒前
3秒前
cc完成签到,获得积分10
3秒前
金澜完成签到 ,获得积分10
4秒前
dzh发布了新的文献求助10
4秒前
学术小白two完成签到,获得积分10
4秒前
FashionBoy的应助被huhuiya采纳,获得10
5秒前
Akim的应助被拼搏的似狮采纳,获得10
5秒前
5秒前
erichohos发布了新的文献求助10
5秒前
aaa完成签到,获得积分10
5秒前
Tony发布了新的文献求助10
5秒前
6秒前
鹤这暴脾气完成签到,获得积分10
6秒前
369ninja发布了新的文献求助10
6秒前
mmy完成签到,获得积分20
6秒前
建成发布了新的文献求助30
7秒前
7秒前
7秒前
笑然发布了新的文献求助10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180531
求助须知:如何正确求助?哪些是违规求助? 9570507
关于积分的说明 21812974
捐赠科研通 7776619
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557539
邀请新用户注册赠送积分活动 2479185